DOLBY LABORATORIES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 81.63 USD | -1.28% |
|
-1.14% | -5.28% |
| May. 03 | Dolby Laboratories Fiscal Q2 Adjusted Earnings Rise, Revenue Declines; Issues Fiscal Q3 Outlook | MT |
| May. 02 | Transcript : Dolby Laboratories, Inc., Q2 2024 Earnings Call, May 02, 2024 |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- With an expected P/E ratio at 32.2 and 28.95 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Software
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -5.28% | 7.92B | B | ||
| -19.23% | 217B | B | ||
| -6.23% | 68.84B | B- | ||
| -0.69% | 58.49B | B | ||
| -9.53% | 47.36B | A- | ||
| +0.78% | 40.57B | C | ||
| -5.82% | 34.3B | B | ||
| -9.95% | 28.69B | B | ||
| +110.79% | 27.82B | - | ||
| +4.41% | 22.03B | B |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- DLB Stock
- Ratings Dolby Laboratories, Inc.